119 related articles for article (PubMed ID: 16467680)
21. In vivo release and retinal toxicity of cyclosporine-loaded intravitreal device.
de Almeida FP; Saliba JB; Ribeiro JA; Siqueira RC; Fialho SL; Silva-Cunha A; Jorge R; Messias A
Doc Ophthalmol; 2015 Dec; 131(3):207-14. PubMed ID: 26576763
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effect of retinoic acid in 1% sodium hyaluronate in an animal model of PVR.
Takahashi M; Refojo MF; Nakagawa M; Veloso A; Leong FL
Curr Eye Res; 1997 Jul; 16(7):703-9. PubMed ID: 9222089
[TBL] [Abstract][Full Text] [Related]
23. The novel use of decorin in prevention of the development of proliferative vitreoretinopathy (PVR).
Nassar K; Lüke J; Lüke M; Kamal M; Abd El-Nabi E; Soliman M; Rohrbach M; Grisanti S
Graefes Arch Clin Exp Ophthalmol; 2011 Nov; 249(11):1649-60. PubMed ID: 21735240
[TBL] [Abstract][Full Text] [Related]
24. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits.
Hashizoe M; Ogura Y; Takanashi T; Kunou N; Honda Y; Ikada Y
Curr Eye Res; 1997 Jul; 16(7):633-9. PubMed ID: 9222079
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid-loaded alginate microspheres as a slow release drug delivery carrier for intravitreal treatment.
Wang F; He S; Chen B
Biomed Pharmacother; 2018 Jan; 97():722-728. PubMed ID: 29102915
[TBL] [Abstract][Full Text] [Related]
26. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
Rahimy MH; Peyman GA; Fernandes ML; el-Sayed SH; Luo Q; Borhani H
J Ocul Pharmacol; 1994; 10(3):561-70. PubMed ID: 7836865
[TBL] [Abstract][Full Text] [Related]
27. Antiproliferative effect of intravitreal alpha-tocopherol and alpha-tocopheryl-acid-succinate in a rabbit model of PVR.
Larrosa JM; Veloso AA; Leong FL; Refojo MF
Curr Eye Res; 1997 Oct; 16(10):1030-5. PubMed ID: 9330855
[TBL] [Abstract][Full Text] [Related]
28. The Effects of Ozurdex® (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy.
Kuo HK; Chen YH; Wu PC; Kuo YH
Ophthalmologica; 2015; 233(3-4):198-203. PubMed ID: 25721986
[TBL] [Abstract][Full Text] [Related]
29. Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Kuo HK; Wu PC; Yang PM; Chen YH; Wu YC; Hu DN
J Ocul Pharmacol Ther; 2007 Feb; 23(1):14-20. PubMed ID: 17341145
[TBL] [Abstract][Full Text] [Related]
30. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.
Yang CS; Khawly JA; Hainsworth DP; Chen SN; Ashton P; Guo H; Jaffe GJ
Arch Ophthalmol; 1998 Jan; 116(1):69-77. PubMed ID: 9445210
[TBL] [Abstract][Full Text] [Related]
31. The effect of tranilast on experimental proliferative vitreoretinopathy.
Ito S; Sakamoto T; Tahara Y; Goto Y; Akazawa K; Ishibashi T; Inomata H
Graefes Arch Clin Exp Ophthalmol; 1999 Aug; 237(8):691-6. PubMed ID: 10459620
[TBL] [Abstract][Full Text] [Related]
32. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil.
Rubsamen PE; Davis PA; Hernandez E; O'Grady GE; Cousins SW
Arch Ophthalmol; 1994 Mar; 112(3):407-13. PubMed ID: 8129669
[TBL] [Abstract][Full Text] [Related]
33. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes.
Xie L; Sun J; Yao Z
Graefes Arch Clin Exp Ophthalmol; 2003 Apr; 241(4):309-13. PubMed ID: 12719992
[TBL] [Abstract][Full Text] [Related]
34. [Experimental study of low molecular weight heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes].
Dai YH; Xie LX; Wu XG; Huang YS; Gong HQ; Yin HM
Zhonghua Yan Ke Za Zhi; 2009 Nov; 45(11):1033-8. PubMed ID: 20137424
[TBL] [Abstract][Full Text] [Related]
35. Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin.
Kuo HK; Chen YH; Wu PC; Wu YC; Huang F; Kuo CW; Lo LH; Shiea J
Invest Ophthalmol Vis Sci; 2012 Jun; 53(6):3167-74. PubMed ID: 22491400
[TBL] [Abstract][Full Text] [Related]
36. A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.
Chen M; Hou J; Tan G; Xie P; Freeman WR; Beadle JR; Hostetler KY; Cheng L
Drug Deliv; 2017 Nov; 24(1):1703-1712. PubMed ID: 29115885
[TBL] [Abstract][Full Text] [Related]
37. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis.
Sakurai E; Matsuda Y; Ozeki H; Kunou N; Nakajima K; Ogura Y
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):2043-8. PubMed ID: 11481270
[TBL] [Abstract][Full Text] [Related]
38. Scleral plug of biodegradable polymers for controlled drug release in the vitreous.
Hashizoe M; Ogura Y; Kimura H; Moritera T; Honda Y; Kyo M; Hyon SH; Ikada Y
Arch Ophthalmol; 1994 Oct; 112(10):1380-4. PubMed ID: 7945044
[TBL] [Abstract][Full Text] [Related]
39. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy.
Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin.
de Souza OF; Sakamoto T; Kimura H; Koda RP; Gabrielian K; Spee C; Ryan SJ
Ophthalmologica; 1995; 209(4):212-6. PubMed ID: 8545096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
